Skip to main content

Prostate Cancer News (Page 6)

Related terms: Cancer, Prostate, Carcinoma of Prostate

Men: Here Are the Health Screenings You Need

MONDAY, June 5, 2023 – Many men will put off going to the doctor unless they are really sick, but men's health screenings help catch problems before symptoms appear. So, how can you tell if a health...

Prostate Cancer: The Basics Every Man Needs to Know

MONDAY, June 5, 2023 – No man wants to hear that he has prostate cancer, but if he is diagnosed he will need to learn about the disease and how it is treated. Prostate cancer affects one in seven...

Need a Prostate Exam? Here's What to Expect

WEDNESDAY, May 31, 2023 – You're due for a prostate exam, but you don't know what to expect. So, what is this exam like? Regular check-ups are essential for maintaining your health, and a prostate...

Prostatitis: What It Is, Symptoms, Causes & Treatment

WEDNESDAY, May 31, 2023 – When most men think about their prostate, it's to worry about whether they have prostate cancer or not. But another condition is far more common and plenty painful....

Differences in Treatment, Not Genes, Keep Black Mens' Prostate Cancer Death Rates High

TUESDAY, May 30, 2023 – Black men die from prostate cancer more frequently than other men. They also shoulder the greatest burden of advanced prostate disease around the world. Now, new research...

Transient Benefit in Outcomes Seen With Androgen Suppression + RT for Prostate Cancer

WEDNESDAY, May 24, 2023 – For patients with intermediate-risk prostate cancer, adding total androgen suppression (TAS) to dose-escalated radiation therapy (RT) yields transient clinically meaningful...

Extra Pounds in Youth Could Raise a Man's Odds for Fatal Prostate Cancer Decades Later

WEDNESDAY, May 17, 2023 – When young men pack on excess weight during their teens and 20s, they may inadvertently drive up their risk for prostate cancer later on. The concern stems from new...

Transgender Women May Be Underdiagnosed With Prostate Cancer

WEDNESDAY, May 3, 2023 – Prostate cancer is not that rare among transgender women, according to a research letter published online April 29 in the Journal of the American Medical Association....

FDA Approves Expanded Indication for Telix’s Illuccix to Include Patient Selection for PSMA-Directed Radioligand Therapy

Indianapolis, IN (United States) | 16 March 2023 – Telix Pharmaceuticals today announces that the United States Food and Drug Administration (FDA) has approved a supplementary New Drug Application...

U.S. FDA Approves Additional Indication of Nubeqa (darolutamide) in Combination with Docetaxel for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Nubeqa now has indications in both metastatic hormone-sensitive prostate cancer (mHSPC) and non-metastatic castration-resistant prostate cancer (nmCRPC)1 Today’s approval under the FDA’s Real-Time On...

FDA Approves Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Targeted Radioligand Therapy for Treatment of Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

FDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions2 Metastatic prostate cancer has a 5-year...

FDA Approves Illuccix (gallium Ga 68 gozetotide) for Prostate Cancer Imaging

Melbourne (Australia) and Indianapolis, IN (U.S.A.) – 20 December 2021. Telix announces the FDA has approved Illuccix®, Telix’s lead prostate cancer imaging product. Telix is pleased to announce that ...

FDA Approves Pylarify (piflufolastat F 18) PSMA-Targeted PET Imaging Drug for Men with Prostate Cancer

May 27, 2021 – FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with p...

FDA Approves Camcevi (leuprolide mesylate) for the Treatment of Advanced Prostate Cancer

TAIPEI, May 26, 2021 /PRNewswire/ – Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for...

FDA Approves Orgovyx (relugolix) as the First Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer

BASEL, Switzerland, Dec. 18, 2020 (GLOBE NEWSWIRE) – Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that the U.S. Food and Drug...

Ask a question

To post your own question to this support group, sign in or create an account.

Further information

Related condition support groups

Cancer

Related drug support groups

Lupron, estradiol, Lupron Depot, Premarin, Estrace, Xtandi